Leading the vaccinal route to defeat the COVID-19 pandemic, Pune based Serum Institute of India (SII) is set to significantly expand its manufacturing of the Covishield vaccine developed by the University of Oxford and pharmaceutical giant AstraZeneca, Livemint.
Having already produced five crore doses of the said vaccine, the Adar Poonawalla led SII is now aiming to manufacture 10 crore doses of the vaccine each month starting 2021. This gains significance as the company has already applied to the Indian regulator, Drug Controller General of India (DCGI) for an emergency use authorisation (EUA).
As per details shared by Poonawalla, SII is working to increase its capacity to produce as many as 250 crore doses a year by the end of 2021. The company has already expanded its capacity to produce as many as 150 crore vaccines annually.
It should be noted that Poonawalla has already stated that for SII, which is the world's largest vaccine maker, India shall be the priority market for the delivery of Covishield stocks, following which it would look to supply stocks to COVAX batch of nations which are mainly based in Africa.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.